Erik Wilker
Impact in
- Cell Biology top 5%
- Microtubule and mitosis dynamics
- Molecular Biology top 10%
- 14-3-3 protein interactions
- Ubiquitin and proteasome pathways
- DNA Repair Mechanisms
- PI3K/AKT/mTOR signaling in cancer
Papers in
-
- Ubiquitin and proteasome pathways 7
- PI3K/AKT/mTOR signaling in cancer 5
- 14-3-3 protein interactions 4
- Cancer-related gene regulation 4
- Protein Tyrosine Phosphatases 2
- Oncology 9
- Cancer-related Molecular Pathways 4
- Peptidase Inhibition and Analysis 3
- Co-authors
- Michael B. Yaffe (10 shared papers)Stephen C. Artim (2 shared papers)Robert A. Grant (1 shared paper)Joseph L. Kissil (2 shared papers)Tyler Jacks (2 shared papers)Kristen C. Johnson (1 shared paper)Matthew S. Eckman (1 shared paper)Yun Feng (2 shared papers)
- Journals
- Cancer Research (5 papers)Molecular Carcinogenesis (2 papers)Molecular Cell (2 papers)Journal of Biological Chemistry (2 papers)Molecular Cancer Therapeutics (1 paper)
- Partner nations
- United StatesCanadaSwitzerland
In The Last Decade
Erik Wilker
23 papers receiving 1.5k citations
Peers
Comparison fields: 5 of 84
- Cell Biology 270
- Molecular Biology 1.1k
- Oncology 268
- Neurology 127
- Immunology 138
Countries citing papers authored by Erik Wilker
This map shows the geographic impact of Erik Wilker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erik Wilker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erik Wilker more than expected).
Fields of papers citing papers by Erik Wilker
This network shows the impact of papers produced by Erik Wilker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erik Wilker. The network helps show where Erik Wilker may publish in the future.
Co-authors
The 25 scholars most cited alongside Erik Wilker, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 24 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2004 | 208 | |
| 2 | 2005 | 203 | |
| 3 | 2003 | 199 | |
| 4 | 2002 | 180 | |
| 5 | 2007 | 176 | |
| 6 | 2006 | 120 | |
| 7 | 2004 | 90 | |
| 8 | 2005 | 60 | |
| 9 | 2008 | 55 | |
| 10 | 2024 | 34 | |
| 11 | 2007 | 30 | |
| 12 | 2022 | 28 | |
| 13 | 1999 | 27 | |
| 14 | M2698 is a potent dual-inhibitor of p70S6K and Akt that affects tumor growth in mouse models of cancer and crosses the blood-brain barrier. | 2016 | 24 |
| 15 | 2023 | 20 | |
| 16 | 1996 | 15 | |
| 17 | 2022 | 5 | |
| 18 | 2022 | 3 | |
| 19 | 2023 | 3 | |
| 20 | 2025 | 1 |
About Erik Wilker
Erik Wilker is a scholar working on Molecular Biology, Oncology, Hematology, Cell Biology and Genetics, having authored 24 papers that have together received 1.5k indexed citations. Recurring topics across this work include Ubiquitin and proteasome pathways (7 papers), PI3K/AKT/mTOR signaling in cancer (5 papers), Cancer-related Molecular Pathways (4 papers), 14-3-3 protein interactions (4 papers), Cancer-related gene regulation (4 papers), Microtubule and mitosis dynamics (3 papers), Peptidase Inhibition and Analysis (3 papers) and Protein Tyrosine Phosphatases (2 papers). The work is most often cited by research in Cell Biology (270 citations), Molecular Biology (1.1k citations), Oncology (268 citations), Neurology (127 citations) and Immunology (138 citations). Erik Wilker has collaborated with scholars based in United States, Canada and Switzerland. Frequent co-authors include Michael B. Yaffe, Stephen C. Artim, Robert A. Grant, Joseph L. Kissil, Tyler Jacks, Kristen C. Johnson, Matthew S. Eckman, Yun Feng, John DiGiovanni and L.F. Haire. Their work appears in journals such as Cancer Research, Molecular Carcinogenesis, Molecular Cell, Journal of Biological Chemistry and Molecular Cancer Therapeutics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.